FDA 483 - Eli Lilly & Company - June 16, 2023
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of Eli Lilly and Company's drug product manufacturing facility in Indianapolis, Indiana, revealed three observations. Deficiencies included failure to follow sanitization procedures for equipment in critical areas, inadequate laboratory practices for test sample traceability, and insufficient validation of sterilization equipment. These issues highlight concerns with adherence to established procedures and validation protocols critical for drug product quality and purity.
ID · ad3d5c22-c165-4f63-91cc-163c31217be2